Key Highlights

  • Statera Biopharma developed immunotherapies targeting autoimmune and inflammatory diseases, neutropenia, emerging viruses, and cancers.
  • Tivic Health Systems announced it acquired worldwide exclusive license rights to Entolimod, a late-stage TLR5 agonist that had been one of Statera's lead assets.
  • The company's SEC filing history on EDGAR runs through late 2022 and early 2023, after which routine reporting appears to have lapsed.
  • STAB trades near $0.0002 with a market Capitalization in the low tens of thousands of dollars in the last closing session.

Statera Biopharma, Inc. (OTC:STAB) entered the public markets with an ambitious immunotherapy pipeline and a portfolio of drug candidates aimed at autoimmune disease, radiation injury and cancer. Today the reality is starker: its most valuable asset has been licensed away to another company.

Company and Latest Development

Based in Fort Collins, Colorado and incorporated in Delaware, Statera Biopharma described itself as a clinical-stage biopharmaceutical company developing immunotherapies targeting autoimmune and inflammatory diseases, neutropenia and anemia, emerging viruses, and cancers. Its SEC filing history on EDGAR runs through late 2022 and early 2023, after which routine reporting appears to have lapsed.

The most concrete recent development is external: Tivic Health Systems (TIVC) announced it had acquired worldwide exclusive license rights to Entolimod, a late-stage Toll-like Receptor 5 (TLR5) agonist that had been one of Statera's lead assets. That transaction effectively moved a key program out of Statera's own hands.

What Is Driving Attention Around STAB?

No verified, company-generated catalyst explains current interest in STAB. The stock is pinned at sub-penny levels with negligible liquidity, where the price barely moves because trading is minimal.

The Entolimod licensing to Tivic Health is the most material recent event tied to Statera's assets, but it benefits the licensee's programs rather than reviving Statera's own listing.

Key Numbers and Company Position

Verifiable figures are limited. Market-data sources show STAB near $0.0002 per share with a market capitalization in the low tens of thousands of dollars, consistent with a distressed, largely inactive listing.

With SEC reporting apparently lapsed since around early 2023, current cash, Debt and operating expenses cannot be independently confirmed, and any pipeline valuation is speculative. Earlier corporate history also included a non-binding letter of intent regarding a proposed Merger with Worksite Labs.

What Could Come Next?

Given the licensing of Entolimod, Statera's own forward catalysts are unclear. Potential developments to watch, through primary sources, include any resumption of SEC filings, disclosure of remaining pipeline rights, a merger or reverse-merger transaction, or news of milestone or Royalty Economics from the Tivic Health license.

None of these is on a confirmed, published timeline, so investors have little concrete to anchor expectations to.

Risks to Watch

The risks are substantial. Lapsed reporting means limited transparency and possible going-concern uncertainty. Sub-penny OTC trading carries extreme illiquidity, Volatility and a genuine risk of total loss.

Having licensed out a lead asset, Statera's remaining value proposition is harder to assess, and any future financing would likely be dilutive.

The Asset Moved On; Statera Stayed Behind

Statera Biopharma's trajectory, from a multi-program immunotherapy developer to a sub-penny listing whose flagship TLR5 asset now sits with another company, captures how quickly a clinical-stage story can stall. With shares near a fraction of a cent, apparently lapsed SEC reporting and its lead program licensed to Tivic Health, STAB is a speculative, distressed name.

Investors may want to monitor EDGAR and any Tivic Health disclosures for signs of remaining value, while weighing the significant Liquidity and transparency risks.